BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhang X, Li J, Yan M. Targeted hepatocellular carcinoma therapy: transferrin modified, self-assembled polymeric nanomedicine for co-delivery of cisplatin and doxorubicin. Drug Dev Ind Pharm 2016;42:1590-9. [PMID: 26942448 DOI: 10.3109/03639045.2016.1160103] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 3.7] [Reference Citation Analysis]
Number Citing Articles
1 Magalhães M, Figueiras A, Veiga F. Smart micelleplexes. Design and Development of New Nanocarriers. Elsevier; 2018. pp. 257-91. [DOI: 10.1016/b978-0-12-813627-0.00007-7] [Cited by in Crossref: 6] [Article Influence: 1.5] [Reference Citation Analysis]
2 Ren Q, Xiao X, Leng X, Zhang Q, Zhou X, Ren Z, Xiao H. MicroRNA-361-5p induces hepatocellular carcinoma cell apoptosis and enhances drug sensitivity by targeting MAP3K9. Exp Ther Med 2021;21:574. [PMID: 33850546 DOI: 10.3892/etm.2021.10006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Scheeren LE, Nogueira-Librelotto DR, Mathes D, Pillat MM, Macedo LB, Mitjans M, Vinardell MP, Rolim CMB. Multifunctional PLGA nanoparticles combining transferrin-targetability and pH-stimuli sensitivity enhanced doxorubicin intracellular delivery and in vitro antineoplastic activity in MDR tumor cells. Toxicol In Vitro 2021;75:105192. [PMID: 33984456 DOI: 10.1016/j.tiv.2021.105192] [Reference Citation Analysis]
4 Younis MA, Khalil IA, Harashima H. Gene Therapy for Hepatocellular Carcinoma: Highlighting the Journey from Theory to Clinical Applications. Adv Therap 2020;3:2000087. [DOI: 10.1002/adtp.202000087] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Kuzajewska D, Wszołek A, Żwierełło W, Kirczuk L, Maruszewska A. Magnetotactic Bacteria and Magnetosomes as Smart Drug Delivery Systems: A New Weapon on the Battlefield with Cancer? Biology (Basel) 2020;9:E102. [PMID: 32438567 DOI: 10.3390/biology9050102] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
6 Turato C, Balasso A, Carloni V, Tiribelli C, Mastrotto F, Mazzocca A, Pontisso P. New molecular targets for functionalized nanosized drug delivery systems in personalized therapy for hepatocellular carcinoma. J Control Release 2017;268:184-97. [PMID: 29051062 DOI: 10.1016/j.jconrel.2017.10.027] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
7 Chi X, Liu K, Luo X, Yin Z, Lin H, Gao J. Recent advances of nanomedicines for liver cancer therapy. J Mater Chem B 2020;8:3747-71. [DOI: 10.1039/c9tb02871d] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
8 Esnaashari SS, Muhammadnejad S, Amanpour S, Amani A. A Combinational Approach Towards Treatment of Breast Cancer: an Analysis of Noscapine-Loaded Polymeric Nanoparticles and Doxorubicin. AAPS PharmSciTech 2020;21:166. [PMID: 32504144 DOI: 10.1208/s12249-020-01710-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
9 Ma Z, Zhang B, Fan Y, Wang M, Kebebe D, Li J, Liu Z. Traditional Chinese medicine combined with hepatic targeted drug delivery systems: A new strategy for the treatment of liver diseases. Biomed Pharmacother 2019;117:109128. [PMID: 31234023 DOI: 10.1016/j.biopha.2019.109128] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
10 Mohamed NK, Hamad MA, Hafez MZ, Wooley KL, Elsabahy M. Nanomedicine in management of hepatocellular carcinoma: Challenges and opportunities: Nanomedicine in management of HCC. Int J Cancer 2017;140:1475-84. [DOI: 10.1002/ijc.30517] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 4.8] [Reference Citation Analysis]
11 Gao Z, Li Z, Yan J, Wang P. Irinotecan and 5-fluorouracil-co-loaded, hyaluronic acid-modified layer-by-layer nanoparticles for targeted gastric carcinoma therapy. Drug Des Devel Ther 2017;11:2595-604. [PMID: 28919710 DOI: 10.2147/DDDT.S140797] [Cited by in Crossref: 22] [Cited by in F6Publishing: 11] [Article Influence: 4.4] [Reference Citation Analysis]
12 Pho-Iam T, Punnakitikashem P, Somboonyosdech C, Sripinitchai S, Masaratana P, Sirivatanauksorn V, Sirivatanauksorn Y, Wongwan C, Nguyen KT, Srisawat C. PLGA nanoparticles containing α-fetoprotein siRNA induce apoptosis and enhance the cytotoxic effects of doxorubicin in human liver cancer cell line. Biochem Biophys Res Commun 2021;553:191-7. [PMID: 33774221 DOI: 10.1016/j.bbrc.2021.03.086] [Reference Citation Analysis]
13 Hu L, Zhang T, Liu D, Guan G, Huang J, Proksch P, Chen X, Lin W. Notoamide-type alkaloid induced apoptosis and autophagy via a P38/JNK signaling pathway in hepatocellular carcinoma cells. RSC Adv 2019;9:19855-68. [DOI: 10.1039/c9ra03640g] [Cited by in Crossref: 10] [Article Influence: 3.3] [Reference Citation Analysis]
14 Choi JY, Thapa RK, Yong CS, Kim JO. Nanoparticle-based combination drug delivery systems for synergistic cancer treatment. Journal of Pharmaceutical Investigation 2016;46:325-39. [DOI: 10.1007/s40005-016-0252-1] [Cited by in Crossref: 58] [Cited by in F6Publishing: 45] [Article Influence: 9.7] [Reference Citation Analysis]
15 Du Y, Liu D, Du Y. Recent advances in hepatocellular carcinoma therapeutic strategies and imaging-guided treatment. J Drug Target 2021;:1-15. [PMID: 34727794 DOI: 10.1080/1061186X.2021.1999963] [Reference Citation Analysis]
16 Zhu B, Zhang H, Yu L. Novel transferrin modified and doxorubicin loaded Pluronic 85/lipid-polymeric nanoparticles for the treatment of leukemia: In vitro and in vivo therapeutic effect evaluation. Biomed Pharmacother 2017;86:547-54. [PMID: 28024291 DOI: 10.1016/j.biopha.2016.11.121] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.7] [Reference Citation Analysis]
17 Fawzi Kabil M, Nasr M, El-Sherbiny IM. Conventional and hybrid nanoparticulate systems for the treatment of hepatocellular carcinoma: An updated review. Eur J Pharm Biopharm 2021;167:9-37. [PMID: 34271117 DOI: 10.1016/j.ejpb.2021.07.003] [Reference Citation Analysis]
18 Chen D, Xie F, Sun D, Yin C, Gao J, Zhong Y. Nanomedicine-Mediated Combination Drug Therapy in Tumor. PHARMSCI 2017;4:1-10. [DOI: 10.2174/1874844901704010001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
19 Scheeren LE, Nogueira-librelotto DR, Macedo LB, de Vargas JM, Mitjans M, Vinardell MP, Rolim CMB. Transferrin-conjugated doxorubicin-loaded PLGA nanoparticles with pH-responsive behavior: a synergistic approach for cancer therapy. J Nanopart Res 2020;22. [DOI: 10.1007/s11051-020-04798-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
20 Sudha T, Bharali DJ, Yalcin M, Darwish NH, Debreli Coskun M, Keating KA, Lin HY, Davis PJ, Mousa SA. Targeted delivery of paclitaxel and doxorubicin to cancer xenografts via the nanoparticle of nano-diamino-tetrac. Int J Nanomedicine 2017;12:1305-15. [PMID: 28243091 DOI: 10.2147/IJN.S123742] [Cited by in Crossref: 25] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
21 Zhang J, Wang X, Cheng L, Yuan J, Zhong Z. SP94 peptide mediating highly specific and efficacious delivery of polymersomal doxorubicin hydrochloride to hepatocellular carcinoma in vivo. Colloids Surf B Biointerfaces 2021;197:111399. [PMID: 33075660 DOI: 10.1016/j.colsurfb.2020.111399] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
22 Baboci L, Capolla S, Di Cintio F, Colombo F, Mauro P, Dal Bo M, Argenziano M, Cavalli R, Toffoli G, Macor P. The Dual Role of the Liver in Nanomedicine as an Actor in the Elimination of Nanostructures or a Therapeutic Target. J Oncol 2020;2020:4638192. [PMID: 32184825 DOI: 10.1155/2020/4638192] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
23 Dutta R, Mahato RI. Recent advances in hepatocellular carcinoma therapy. Pharmacol Ther. 2017;173:106-117. [PMID: 28174094 DOI: 10.1016/j.pharmthera.2017.02.010] [Cited by in Crossref: 120] [Cited by in F6Publishing: 124] [Article Influence: 24.0] [Reference Citation Analysis]
24 Chowdhury MMH, Salazar CJJ, Nurunnabi M. Recent advances in bionanomaterials for liver cancer diagnosis and treatment. Biomater Sci 2021;9:4821-42. [PMID: 34032223 DOI: 10.1039/d1bm00167a] [Reference Citation Analysis]
25 Lei J, Cong S, Song M, Zhang W, Peng G, Li X, Liu Y. Combination of doxorubicin with harmine-loaded liposomes exerting synergistic antitumor efficacy. Drug Dev Ind Pharm 2018;44:570-81. [PMID: 29260918 DOI: 10.1080/03639045.2017.1405432] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
26 Kumar V, Rahman M, Gahtori P, Al-Abbasi F, Anwar F, Kim HS. Current status and future directions of hepatocellular carcinoma-targeted nanoparticles and nanomedicine. Expert Opin Drug Deliv 2021;18:673-94. [PMID: 33295218 DOI: 10.1080/17425247.2021.1860939] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]